Daily Endocrinology Research Analysis
Analyzed 120 papers and selected 3 impactful papers.
Summary
Three impactful endocrinology-related studies stood out: a large trial-level meta-analysis linked greater on-treatment eGFR improvement with larger heart failure risk reduction from GLP-1 receptor agonists; a network meta-analysis across 7.1 million patients showed antihyperglycemic drug classes differ in their associations with major adverse liver outcomes; and a phase II basket trial found the CNP analog vosoritide markedly increases growth velocity across RASopathies/ACAN/NPR2 deficiency, albeit with notable orthopedic adverse events.
Research Themes
- Cardiorenal mechanisms and outcomes with GLP-1 receptor agonists
- Differential hepatic risk across antihyperglycemic drug classes
- Precision growth therapy targeting MAPK pathway disorders
Selected Articles
1. Estimated Glomerular Filtration Rate Change and Heart Failure Events With GLP-1 Receptor Agonists: A Meta-Analysis and Meta-Regression of Randomised Controlled Trials.
Across 11 large RCTs (90,867 participants), GLP-1 receptor agonists reduced clinical heart failure events (HR 0.86). Trial-level meta-regression showed that greater annualized eGFR improvement was associated with larger HF risk reduction, suggesting kidney function change may be an on-treatment marker of HF benefit with GLP-1RAs.
Impact: Links cardiorenal biology to clinical outcomes and proposes eGFR change as a pragmatic surrogate for HF benefit, informing monitoring strategies and trial design.
Clinical Implications: When prescribing GLP-1RAs, monitor annualized eGFR change as a potential indicator of heart failure risk reduction. This may aid risk stratification and therapeutic monitoring alongside standard cardiometabolic targets.
Key Findings
- GLP-1RAs reduced clinical heart failure events across 11 RCTs (HR 0.86, 95% CI 0.80–0.93).
- Greater annualized eGFR improvement correlated with larger HF risk reduction in mixed-effects meta-regression.
- Associations were examined alongside changes in body weight, SBP, and heart rate, highlighting a specific link to kidney function change.
Methodological Strengths
- Trial-level meta-analysis of large-scale randomized, placebo-controlled studies
- Pre-specified mixed-effects meta-regression evaluating multiple on-treatment markers
Limitations
- Trial-level (not individual patient-level) meta-regression may be prone to ecological bias
- Heterogeneity in HF endpoint definitions and background therapies across trials
Future Directions: Patient-level meta-analyses to confirm the eGFR–HF relationship; prospective studies to validate eGFR change as a surrogate endpoint for HF benefit with GLP-1RAs.
AIMS: To examine whether on-treatment changes in kidney function and cardiometabolic markers are associated with the magnitude of heart failure (HF) risk reduction across large-scale trials of glucagon-like peptide-1 receptor agonists (GLP-1RAs). MATERIALS AND METHODS: We searched PubMed and Embase from inception to 29 January 2026 for randomised, placebo-controlled GLP-1RA trials enrolling ≥ 1000 adults with type 2 diabetes and/or overweight or obesity and a follow-up of at least one year. The primary outcome was clinical HF events (hospitalisation for HF, with or without urgent HF visits). We pooled hazard ratios (HRs) using random-effects meta-analysis and performed mixed-effects meta-regression to test whether between-group changes in annualised estimated glomerular filtration rate (eGFR) improvement, body weight, systolic blood pressure (SBP), and heart rate were associated with the treatment effect on clinical HF events. RESULTS: Eleven trials were included (90 867 participants; 2863 clinical HF events). GLP-1RAs reduced the risk of clinical HF events (HR 0.86, 95% CI 0.80 to 0.93, p < 0.001, I
2. Hepatic Events Prevention by Antihyperglycemic Therapies and Intervention Comparisons in Type 2 Diabetes: The HEPATIC-T2DM Network Meta-analysis.
Across 46 observational studies (N=7.12 million), hepatic risk varied by antidiabetic class: thiazolidinediones were least associated with HCC incidence, GLP-1RAs with hepatic decompensation and portal-systemic complications, and SGLT2 inhibitors with cirrhosis and liver-related mortality. Findings support class-specific hepatic profiles but cannot establish causality.
Impact: Provides the most comprehensive comparative synthesis of hepatic outcomes across antidiabetic classes, informing individualized therapy in T2DM with concomitant liver disease risk.
Clinical Implications: For T2DM patients at high hepatic risk, consider GLP-1RAs to mitigate decompensation and portal-systemic events, SGLT2 inhibitors for reducing cirrhosis and liver-related mortality, and thiazolidinediones when HCC risk predominates—while balancing overall cardiometabolic profile and acknowledging non-causal evidence.
Key Findings
- Thiazolidinediones showed the lowest association with HCC incidence (e.g., vs DPP-4 inhibitors HR 0.50; vs GLP-1RAs HR 0.72).
- GLP-1RAs were associated with the lowest hazard for hepatic decompensation (HRs 0.16–0.91 vs other classes).
- SGLT2 inhibitors had the lowest association with cirrhosis and liver-related mortality; GLP-1RAs were least associated with variceal bleeding and hepatic encephalopathy.
Methodological Strengths
- Three-level Bayesian network meta-analysis with study- and database-level random effects
- Very large aggregated sample size enabling precise class comparisons
Limitations
- All data are observational with residual confounding and channeling bias
- Outcome definitions and exposure ascertainment vary across databases
Future Directions: Pragmatic randomized trials and emulation studies in high-risk T2DM populations to test liver-specific outcomes; mechanistic work to explain class differences.
BACKGROUND: Type 2 diabetes mellitus (T2DM) amplifies liver disease burden, yet the comparative hepatic effects of antidiabetic drugs remain poorly defined. PURPOSE: To compare associations between antidiabetic drug classes and major adverse liver outcomes (MALOs) in adults with T2DM. DATA SOURCES: PubMed, EMBASE, and Cochrane Central Register of Controlled Trials were searched from December 1946 through 23 August 2025. STUDY SELECTION: Studies enrolling adults with T2DM that evaluated associations between antidiabetic drug classes with regard to MALOs were included. DATA EXTRACTION: Data were extracted on study characteristics, drug exposures, and MALOs. DATA SYNTHESIS: A three-level Bayesian network meta-analysis with study- and database-level random effects was performed. Outcomes are reported as hazard ratios (HRs) and ranked using the surface under the cumulative ranking curve. Forty-six observational studies (N = 7,124,845) were included. Thiazolidinediones were least associated with hepatocellular carcinoma incidence and significantly lower than DPP-4 inhibitors (HR 0.50), GLP-1RAs (HR 0.72), insulin (HR 0.20), and sulfonylureas (HR 0.69). For decompensation (composite), GLP-1RAs were associated with the lowest hazard compared with all other classes (HRs 0.16-0.91; all significant). SGLT2 inhibitors were least associated with cirrhosis (HR 0.66 vs. DPP-4 inhibitors; HR 0.66 vs. GLP-1RAs). GLP-1RAs were least associated with variceal bleeding and hepatic encephalopathy, whereas SGLT2 inhibitors were least associated with liver-related mortality. LIMITATIONS: All included studies were observational, precluding causal inference. CONCLUSIONS: Liver-specific risk reduction is not uniform across antihyperglycemic drug classes. Randomized trials are needed to determine whether these associations reflect true drug effects.
3. A Phase II Basket Trial of Vosoritide in Children with RASopathies, ACAN and NPR2 Deficiency.
Vosoritide substantially increased annualized growth velocity from 4.53 to 8.09 cm/year and improved height SDS (+0.65) across RASopathies, ACAN, and NPR2 deficiency. While short-term safety was acceptable, longer-term treatment revealed orthopedic adverse events including slipped capital femoral epiphysis and genu valgum.
Impact: Demonstrates pathway-targeted growth promotion beyond achondroplasia, supporting precision endocrinology for diverse genetic short-stature syndromes while surfacing critical safety considerations.
Clinical Implications: Vosoritide may be considered for selected children with MAPK pathway-related short stature, with multidisciplinary monitoring for orthopedic complications (e.g., SCFE, genu valgum) and shared decision-making about risk–benefit.
Key Findings
- Annualized growth velocity increased from 4.53±1.61 to 8.09±1.58 cm/year (p<0.0001), with a +4.0 SD increase in AGV Z-score.
- Height SDS improved by +0.65 compared with the observation period (p<0.0001), with benefit across genetic subgroups.
- Five discontinuations due to adverse events, including 3 slipped capital femoral epiphyses and 4 cases of genu valgum.
Methodological Strengths
- Prospective phase II basket design spanning multiple genetic etiologies
- Within-subject comparison using a 6-month observation lead-in
Limitations
- Small sample size and open-label design limit generalizability
- Orthopedic adverse events raise safety concerns requiring longer-term follow-up
Future Directions: Larger randomized studies with longer follow-up to define benefit–risk, identify predictors of response and skeletal AEs, and refine dosing/monitoring protocols.
CONTEXT: Genetic defects in many biological pathways, including activation of the Ras-MAPK pathway, cause short stature. Vosoritide, a C-type natriuretic peptide analog that inhibits this pathway, has been approved for use in achondroplasia. OBJECTIVE: To determine whether vosoritide improves growth in children with disorders of the Ras-MAPK pathway including RASopathies, ACAN and NPR2 deficiency. DESIGN: Prospective phase 2 basket trial. SETTING: Academic medical center. PARTICIPANTS: Thirty pre-pubertal children aged 3 to 11 years with a RASopathy, ACAN or NPR2 deficiency and height <-2.25 SD. INTERVENTION: 6-month observation period followed by 12-month treatment with vosoritide subcutaneously 15 micrograms/kg/day. MAIN OUTCOME MEASURES: Co-primary outcomes included incidence of adverse events, change in annualized growth velocity (AGV) and height standard deviation scores. RESULTS: The AGV increased from 4.53+1.61 cm/yr to 8.09+1.58 cm/yr with treatment (p<0.0001). This corresponded to a 4.0 SD (95%CI 3.08-4.91) increase in age and sex-adjusted AGV Z-score (p<0.0001). The increase in AGV was seen in all genetic subgroups. There was a height increase of 0.65 SD (95%CI 0.53-0.77) in the treatment versus observation period (p<0.0001).Short-term safety was reassuring with mild injection site reactions being the most common adverse events. However, with longer use, five subjects discontinued medication due to adverse events including three slipped capital femoral epiphyses and four cases of genu valgum. CONCLUSIONS: Vosoritide led to marked increases in growth velocity in children with RASopathies, ACAN and NPR2 deficiency, raising the possibility that vosoritide could be an effective precision medicine for all growth disorders affecting the MAPK pathway.